Tag - CATX

Developments

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced a clinical trial collaboration agreement with Merck (NYSE: MRK) to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda...

September 14, 2026

Developments

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of...

October 2, 2025

Tag - CATX

Perspective and Merck collaborate on study of combined therapies in FAP-α solid tumors

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Subscribe